NL-OMON29756已完成不适用
An Open-label, Phase I Study to determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, administered to Subjects with Advanced Stage and/or Refractory Solid Malignancies - Dose escalation safety and Pharmacokinetic study.
Johnson & Johnson Pharmaceutical0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male or female, Age 18 years or older, Histologically or cytologically confirmed solid malignancy that is advanced stage and/or refractory and progressing and for which standard treatments do not exist or are no longer effective , ECOG Performance Status 0 - 2, Life expectancy > 3 months.
排除标准
- •Known central nervous system metastases, female patient who is pregnant or is breast-feeding, Chemotherapy, radiotherapy, immunotherapy within 4 weeks before dosing with JNJ-26483327, History of uncontrolled heart disease.
研究者
相似试验
进行中（未招募）
1 期
Research study aiming at investigating the potential safety of multiple administrations of NKR-2 after chemotherapy treatment targeting T-cells in patients with acute myeloid leukemia. The NKR-2 treatment is based on patient's own T-cells that will be collected and modified before being injected to generate anti-tumor responses.KR-2 has the potential to treat many distinct tumor-types. This trial will focus on Relapsed and/or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).EUCTR2018-000205-22-BECelyad Onclogy SA17
已完成
1 期
A Study to Determine the Safety and Tolerability of PMZ-1620 in Healthy Volunteers.CTRI/2016/11/007509Pharmazz India Private Limited7
已完成
1 期
A Phase 1, Open-label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Multiple Subcutaneous Doses of Pentosan Polysulfate Sodium (PPS) in Healthy Adult ParticipantsBone Marrow LesionMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disordersInflammatory and Immune System - Other inflammatory or immune system disordersKnee OsteoarthritisACTRN12620000829910Paradigm Biopharmaceuticals Pty Ltd23
已完成
不适用
A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)bloedkankerAcute lymphocytic leukaemiaBlood CancerNL-OMON55298Amgen2
进行中（未招募）
1 期
A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers..Advanced MalignanciesMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003688-73-GBAstraZeneca AB230